Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

186 ta ish

Ish: Outsmarting Antigen Escape: Next‐Generation <scp>CAR</scp> T Cell Engineering Strategies for Durable Remissions in Hematologic Malignancies

  1. Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect

    Chengcheng Feng, Yuting Wang, Jinghua Xu +5

    Maqola202412 iqtibos
    ABI

  2. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies

    Ding-Ya Sun, Yijie Hu, Xin Li +3

    Sharh maqola202411 iqtibos
    ABI

  3. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Sharh maqola20259 iqtibos
    ABI

  4. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Maqola20238 iqtibos
    ABI

  5. The Burgeoning Significance of Liquid-Liquid Phase Separation in the Pathogenesis and Therapeutics of Cancers

    Wei-Xin Xu, Qiang Qu, Hai-Hui Zhuang +5

    Maqola20247 iqtibos
    ABI

  6. CAR-T cell therapy for cancer: current challenges and future directions

    Inés Zugasti, Lady Espinosa-Aroca, Klaudyna Fidyt +7

    Sharh maqola20257 iqtibos
    ABI

  7. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje, Jesús G. Berdeja, Yi Lin +20

    Maqola20195 iqtibos
    ABI

  8. CAR-T cell therapy: current limitations and potential strategies

    Robert C. Sterner, Rosalie M. Sterner

    Sharh maqola20215 iqtibos
    ABI

  9. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy

    Alireza Bayani, Munthar Kadhim Abosaoda, Jasur Rizaev +3

    Sharh maqolaAdvanced biosensing and bioanalysis techniquesClinical and Experimental Medicine20254 iqtibos
    ABI

  10. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

    Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

    Maqola20174 iqtibos
    ABI

  11. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Maqola20184 iqtibos
    ABI

  12. Engineering and Design of Chimeric Antigen Receptors

    Sònia Guedan, Hugo Calderón, Avery D. Posey +1

    Sharh maqola20184 iqtibos
    ABI

  13. Sarlavhasiz

    Boshqa4 iqtibos
    ABI

  14. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

    Margot J. Pont, Tyler Hill, Gabriel O. Cole +14

    Maqola20193 iqtibos
    ABI

  15. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

    Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27

    Maqola20213 iqtibos
    ABI

  16. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  17. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

    Gils Roex, Diana Campillo-Davó, Donovan Flumens +6

    Maqola20223 iqtibos
    ABI

  18. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  19. Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors

    Koichi Hirabayashi, Hongwei Du, Yang Xu +8

    Maqola20213 iqtibos
    ABI

  20. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape

    You Zhai, Yicong Du, Guanzhang Li +9

    Maqola20233 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa2 iqtibos
    ABI